Request Demo
Recent blog posts
Latest Hotspot
8 min read
Rubella vaccine(Tianjin Genstar Biotech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Rubella vaccine(Tianjin Genstar Biotech): Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Evategrel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Evategrel: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Diabetic Macular Edema Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Diabetic Macular Edema clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Human immunoglobulin (Rongsheng) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Human immunoglobulin(China Resources Boya Bio-pharmaceutical): Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP.
Latest Hotspot
8 min read
Neovascular Age-Related Macular Degeneration Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Neovascular Age-Related Macular Degeneration clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and…
Latest Hotspot
8 min read
SCTB-14 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
SCTB-14: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Geographic Atrophy Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Geographic Atrophy clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Yogliptin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Yogliptin: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Food Allergy Immunotherapy Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Food Allergy Immunotherapy clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white…
Latest Hotspot
8 min read
Obstructive Sleep Apnea Pharmacotherapy Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Obstructive Sleep Apnea Pharmacotherapy clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and…
Latest Hotspot
8 min read
HRS-8080 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
HRS-8080: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Pulmonary Sarcoidosis Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Pulmonary Sarcoidosis clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.